# Association between examined lymph node count and survival in resectable cervical cancer: a retrospective analysis using SEER data

## TL;DR

This study found that examining more lymph nodes in cervical cancer patients is linked to better long-term survival, with specific thresholds for different stages.

## Contribution

The study identifies optimal examined lymph node counts for N0 and N1 cervical cancer stages using a large database.

## Key findings

- N0 patients with at least 13 examined lymph nodes had better survival rates.
- N1 patients with at least 14 examined lymph nodes showed improved long-term survival.
- Adjuvant treatments provided greater survival benefits for N1 adequate patients.

## Abstract

The optimal examined lymph node (ELN) in resectable nonmetastatic cervical cancer patients remains controversial.

A total of 7435 N0 patients and 1385 N1 patients were enrolled from the Surveillance, Epidemiology, and End Results database. The relationship between ELN and cancer-specific surcical (CSS) was evaluated by restrictive cubic spline (RCS) method. Survival analysis was performed by using Kaplan–Meier method.

The median ELN count decreased over years both in N0 and N1 patients. The RCS illustrated nonlinear relationships between ELN counts and prognosis for N0 patients (nonlinearity, p= 0.026; optimal ELN: 13) and N1 patients (nonlinearity, p= 0.024; optimal ELN: 14). Patients were divided into ELN adequate and limited groups according to the optimal cutoff of ELN. The 5-yr and 10-yr survival rates were 94.4% and 92.5% for N0 adequate patients, and 93.9% and 90.0% for N0 limited patients. The 5-yr and 10-yr survival rates were 73.8% and 70.3% for N1 adequate patients, and 68.6% and 63.5% for N1 limited patients. For N0 patients, no survival benefit was found in additional adjuvant treatment. For N1 adequate patients, those with adjuvant radiotherapy obtained greatest survival benefit. For N1 limited patients, those with adjuvant radiotherapy or radiotherapy plus chemotherapy obtained better survival.

Nonmetastatic cervical cancer patients with clinical N0 and N1 stages who had at least 13 and 14 ELN counts, respectively, showed better long-term survival. Further prospective studies are needed to validate the association between ELN count and long-term survival.